Treatment of advanced non-small cell lung cancer;Therapie des fortgeschrittenen nichtkleinzelligen bronchialkarzinoms

Onkologe

Volumn 8, Issue 5, 2002, Pages 471-486

  Wolf, M ^a   Gatzemeier, U ^b   Niederle, N ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b KH Gro hansdorf   (Germany)

^c Klinikum Leverkusen GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TENIPOSIDE; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036590645     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00761-002-0315-y     Document Type: Review

References (83)

1. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909
2. Cullen MH, Billingham U, Woodroffe CM et al. (1999) Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life. J Clin Oncol 17: 3188-3194
3. The Elderly Lung Cancer, Vinorelbine Italian Study Group (1999) Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients with Advanced Non-Small-Cell Lung Cancer. JNCI 91: 66-72
4. Anderson H, Hopwood P, Stephens RJ et al. (2000) Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83: 447-453
5. Ranson M, Davidson N, Nicolson M et al. (2000) Randomized trial of Paclitaxel plus Suppotive Care versus Suppotive Care for Patients with Advanced Non Small Cell Lung Cancer, JNCI 92: 1074-1080
6. Roszkowski K, Pluzanska A, Krzakowski M et al. (2000) A multicenter, randomized, phase III study of Docetaxel plus best supportive care versus best supportive care in chemotherapynaïve patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27: 145-157
7. Luedke DW, Einhorn L, Omura GA et al. (1990) Randomized Comparison of Two Combination Regimens Versus Minimal Chemotherapy in Non Small Cell Lung Cancer: A Southeastern Cancer Study Group Trial. J Clin Oncol 8: 886-891
8. Rosso R, Salvati F, Ardizzoni A et al. (1990) Etoposide Versus Etoposide Plus High-Dose Cisplatin in the Management of Advanced Non-Small Cell Lung Cancer. Cancer 66: 130-134
9. Klastersky J, Sculier JP, Bureau G et al. (1989) Cisplatin Versus Cisplatin Plus Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer. J Clin Oncol 7: 1087-1092
10. Crino L, Darwish S, Corgna E et al.(1988) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): The "Umbria" Cooperative Study. Semin Oncol 15(Suppl 7): 52-55
11. Kawahara M, Furuse K, Kodama N et al. (1991) A Randomized Study of Cisplatin versus Cisplatin plus Vindesine for Non-Small Cell Lung Carcinoma. Cancer 68: 714-719
12. JK, Crowley J, Natale RB et al. (1991) A Randomized Trial of Five Cisplatin-Containing Treatments in Patients with metastatic NonSmall Cell Lung Cancer: A Southwest Oncology Group Study. J Clin Oncol 9: 1157-1162
13. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. (1986) A Randomized Trial of the four most active Regimens for metastatic NonSmall Cell Lung Cancer. J Clin Oncol 4: 14-22
14. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. (1989) Combination Chemotherapy versus Single Agents followed by Combination Chemotherapy in Stage IV Non-Small Cell Lung Cancer: A Study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602-1613
15. Gatzemeier U, Heckmayr M, Hossfeld DK et al. (1990) Chemotherapie des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms mit Mitomycin-C/Ifosfamid versus Mitomycin-C/Vindesin versus Cisplatin/Etoposid - Eine prospektiv randomisierte Studie. Pneumologie 44: 258-260
16. Klastersky J, Sculier JP, Lacroix H et al. (1990) A Randomized Study Comparing Cisplatin or Carboplatin with Etoposide in Patients with advanced Non-Small Cell Lung Cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8: 1556-1562
17. Crino L, Clerici M, Figoli F et al (1995) Chemotherapy of advanced non-small cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 6: 347-353
18. Murphy WK, Fossella FU,Winn RJ et al. (1993) A Phase II Study of Taxol (NSC 125973) in Patients with untreated advanced Non-Small Cell Lung Cancer. J Natl Cancer Inst 85: 384-388
19. Gatzemeier U (1995) Development of Paclitaxel and Review of US and European Phase II Data in Lung Cancer. 3rd Central European Lung Cancer Conference, Prague, 28.-31.05.
20. Hainsworth JD, Thompson DG, Greco FA et al. (1995) Paclitaxel by 1-Hour Infusion: An Active Drug in Metastatic Non-Small Cell Lung Cancer. J CliniOncol 13: 1609-1614
21. Akerly W, Glantz M, Choy H et al. (1998) Phase I Trial of Weekly Paclitaxel in Advanced Lung Cancer. J Clin Oncol 16: 153-158
22. Fossella FV, Lee JS, Shin DM et al. (1995) Phase II Study of Docetaxel for Advanced or Metastatic Platinum-Refractory Non-Small-Cell Lung Cancer. J Clin Oncol 13: 645-651
23. Kim NK, Park K, Park CH et al. (1998) Phase II Trial of Docetaxel foradvanced Non-Small-Cell Lung Cancer (NSCLC). Proc ASCO 17, abs. 1886
24. Kunitoh H, Watanabe K, Onoshi T et al. (1996) Phase II Trial of Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer: A Japanese Cooperative Study. J Clin Oncol 14: 1649-1655
25. Manegold C, Pilz L, Koschel K et al. (2001) Single Agent Gemcitabine (G) and Docetaxel (D) Given Sequentially in Various Doses and Schedules Are Effective in Advanced NSCLC: Survival Data from Two (I,II) Randomized Phase II Studies. Proc ASCO 20, abstr. 1346, p 337a
26. Abratt RP, Bezwoda WR, Falkson G et al. (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1450
27. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-Agent Activity of Weekly Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase II Study. J Clin Oncol 12: 1821-1826
28. Gatzemeier U, Shephard F, Le Chevalier T et al. (1994) A multicenter Phase II trial with gemcitabine in non small cell lung cancer (NSCLC). Lung Cancer 11 (Suppl 1) 121 abstr 461
29. Depierre A, Chastang CI, Quoix E et al. (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Annals of Oncology 5: 37-42
30. Crawford J, O'Rourke M, Schiller JH et al. (1996) Randomized Trial of Vinorelbine Compared With Fluorouracil Plus Leucovorin in Patients With Stage IV Non-Small Cell Lung Cancer. J Clin Oncol 14: 2774-2784
31. Furuse K, Fukuoka M, Kuba M et al.(1996) Randomized study of vinorelbine (VRB) versus (VDS) in previously untreated stage IIIB or IV non-small cell lung cancer (NSCLC). Ann Oncol 7: 815-820
32. Fukuoka H, Niitani H, Suzuki A et al. (1992) A Phase II Study of CPT-11, a New Derivative of Camptothecin, for Previously Untreated Non-Small-Cell Lung Cancer. J Clin Oncol 10: 16-20
33. Perez-Soler R, Fossella FV, Glisson B.S et al. (1996) Phase II Study of Topotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Untreated With Chemotherapy. J Clin Oncol 14:503-513
34. White SC, Cheeseman S, Thatcher N et al. (2000) Phase II study of oral Topotecan in advanced non-small cell lung cancer. Clin Cancer Res 6: 868-873
35. Rustoven JJ, Eisenhauser E, Butts C et al. (1999) Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non-Small-Cell Lung Cancer: A Phase II Study. J Clin Oncol 17: 1194-1199
36. Monnet I, Brienza S, Hugret F et al. (1998) Phase II Study of Oxaliplatin in Poo-prognosis Non-Small Cell Lung Cancer (NSCLC). Eur J Cancer 37: 1124-1127
37. Gatzemeier U, von Pawel J, Gottfried M et al. (2000) Phase III Comparative Study of High Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol 18: 3390-3399
38. ten Bokkel Huinink WW, Bergman B, Chemaissani A et al. (1999) Single-agent Gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 26: 85-94
39. Vansteenkiste J, Vandebroek J, Nackaerts K et al. (2000): Symptom Control in Advanced Non-Small Cell Lung Cancer (NSCLC): A Multicenter Prospektive Randomized Phase III Study of Single Agent Gemcitabine (GEM) Versus Cisplatin-Vindesine (PV). Proc ASCO 19, abstr. 1910
40. Sandler A, Nemunaitis J, Dehnam C et al. (1998) Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 17, abstr. 1747
41. LeChevalier T, Brisgand D, Douillard JY et al. (1994) Randomized Study of Vinorelbine and Cisplatin Versus Vindesine and Cisplatin Versus Vinorelbine Alone in Advanced Non-Small-Cell Lung Cancer: Results of a European Multicenter Trial Including 612 Patients. J Clin Oncol 12: 360-367
42. Wozniak AJ, Crowley JJ, Balcerzak SP et al. (1998): Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small lung cancer (NSCLC): an update of a Southwest Oncology Group study (SWOG-9308). Proc ASCO, Vol 17, abstr. 1744
43. Masuda N, Fukooka M, Negoro S et al. (1999) Randomized Trial Comparing Cisplatin (CDDP) and Irinotecan (CPT-11) Versus CDDP and Vindesine (VDS) Versus CPT-11 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC), a Multicenter Phase III Study. Proc ASCO 18, abstr. 1774
44. yon Pawel J, von Roemeling R, Gatzemeier U et al. (2000) Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non-Small Cell Lung Cancer: A Report of the International CATAPULT 1 Study Group. J Clin Oncol 18: 1351-1359
45. Bonomi P, Kim K, Fairclough, D et al. (2000) Comparison of survival and quality of Life in Advanced Non-Small Cell Lung Cancer Patients Treated with two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group TriaI. J Clin Oncol 18: 623-631
46. Giaccone, G, Splinter, TAW, Debruyne C et al. (1998) Randomized Study of Paclitaxel-Cisplatin Versus Cisplatin-Teniposide in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 16: 2133-2141
47. Belani CP, Natale RB, Lee JS et al. (1998) Randomized Phase III Trial Comparing Cisplatin/Etoposide versus Carboplatin/Paclitaxel in advanced and metastatic Non-Small-Cell Lung Cancer. Proc ASCO 17, abstr. 1751
48. Kelly K, Crowley J, Bunn PA et al. (1999) A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (PC) Versus Vinorelbine Plus Cisplatin (VC) in Untreated Advanced Non-SmallCell Lung Cancer (NSCLC): A Southwest Oncology Group (SWOG) Trial. Proc ASCO 18, abstr. 1777
49. Rodriguez J, Pawel J, Pluzanska A et al. (2001) A Multicenter Randomized Phase III Study of Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCB) vs Vinorelbine + Cisplatin (VC) in Chemotherapy Naive Patients with Advanced and Metastatic Non-Small Cell Lung Cancer (NSCLC). Procs ASCO 20, abstr. 1252
50. Kunitoh H, Watanabe K, Ohashi Y et al. (2001) Preliminary results aof a randomised phase III trial of docetaxel (D) and cisplatin (P) versus vindesine (V) and P in stage IV non-small cell lung cancer (NSCLC). Proc ASCO 20, abstr. 12891
51. Georgoulias V, Papadakis E, Alexopoulos A et al. (2001) Platinum based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 357: 1478-1484
52. Crino L, Scagliotti G.V. Ricci S et al. (1999) Gemcitabine and Cisplatin versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A randomized Phase III Study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530
53. Cardenal F, Paz Lopez-Cabrerizo M, Anton A et al. (1999) Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol 17: 12-18
54. Schiller, JH, Harrington D, Belani CP et al. (2002) Comparison of four Chemotherapy Regimens for adanced Non-Small Cell Lung Cancer. N Engl J Med 346: 92-98
55. Scagliotti GV, De Marinis F, Rinaldi M et al. (2001) Phase III Randomized Trial Comparing Three Platinum Based Doublets in Advanced Non-Small Cell Lung Cancer. Proc ASCO 20, abstr. 1227
56. Comella P, Frasci G, Panza N et al. (2000) Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemicitabine or Cisplatin and Vinorelbine in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18: 1451-1457
57. Comella G, Comella P, Frasci G et al. (2000) Cisplatin-Gemcitabine vs Cisplatin-Gemcitabine-Vinorelbine vs Cisplatin-Gemcitabine-Paclitaxel in Advanced Non-Small-Cell Lung Cancer. First Stage Analysis of a Southern Italy Cooperative Oncology Group (SICOG) Phase III Trial. Proc ASCO, Vol. 19, abs. 1933.
58. Alberola V, Camps C, Provencia M et al. (2001) Cisplatin/Gemcitabine (CG) vs Cisplatin/Gemcitabine/Vinorelbine (CGV) vs Sequential Doublets of Gemcitabine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial (GEPC/98-02). Proc ASCO 20,abstr. 1229
59. Tan E, Souquet J, Pereira R et al. (2001) Glob 1: Final Results of a Prospective Randomized Phase III Trial Comparing Vinorelbine and Cisplatin (NP) Versus Vinorelbine, Ifosfamide, and Cisplatin (NIP) in Metastatic Non Small Cell Lung Cancer (NSCLC) Patients (pts). Proc ASCO 20, abstr. 1299, p 326a
60. Kosmidis PA, Bacoyiannis C, Mylonakis N et al. (2000): A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Gemcitabine in Advanced Non Small Cell Lung Cancer (NSCLC). A Preliminary Analysis. Proc ASCO 19, abstr. 1908
61. Van Meerbeek JR, Smit EF, Lianes P et al. (2001) A EORTC Randomized Phase III Trial of Three Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC). Proc ASCO 20, abstr. 1228
62. Belani C, Barstis M, Perry R et al. (2001) Phase II Multicenter Randomized Trial of Weekly Paclitaxel (P) Administered in Combination with Carboplatin (C) Followed by Maintenance P Vs. Observation for Patients (pts) with Advanced & Metastatic Non-Small Cell Lung Cancer (NSCLC). Proc ASCO 20, abstr. 1287, p 323a
63. Fossella FV, Lee JS, Shin DM et al. (1995) Phase II Study of Docetaxel for Advanced or Metastatic Platinum-Refractory Non-Small-Cell Lung Cancer. J Clin Oncol 13: 645-651
64. Crino L, Mosconi AM, Scagliotti G et al. (1999) Gemcitabine as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Phase II Trial. J Clin Oncol 17: 2081-2085
65. Shephard F, Dancey J, Ramlau R et al. (2000) Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. J Clin Oncol 18: 2095-2103
66. Fossella FV, DeVore R, Kerr R et al. (1999) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy
67. Joakkimainen L, Goodwin PJ, Pater J et al. (1990) Counting the Costs of Chemotherapy in a National Cancer Institute of Canada Randomized Trial in Nonsmall-Cell Lung Cancer. J Clin Oncol 8: 1301-1309
68. Earle CC, Evans WK (1999) Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small cell lung cancer. BJC 80: 808-814
69. Goodwin PJ, Shephard FA (1998) Economic Issues in Lung Cancer: A Review. J Clin Oncol 16: 3900-3912
70. Leighl NB, Shephard FA, Kwong R et al. (2001) Economic Analysis of TAX 317: Docetaxel Vs. Best Supportive Care (BSC) for Second-Line Management of Advanced Non-Small Cell Lung Cancer (NSCLC). Proc ASCO 20, abstr. 1291
71. Berthelot JM, Will BP, Evan K et al. (2000) Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small Cell Lung Cancer. J Natl Cancer Inst 92: 1321-1329
72. Cullen MH (1995) Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Lung Cancer 12: 95-106
73. Raby B, Pater J, Mackillop WJ (1995) Does Knowledge Guide Practice? Another Look at the Management of Non-Small Cell Lung Cancer. J Clin Oncol 13: 1904-1911
74. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771-775
75. Soria JC, Brisgand D, LeChevalier T (2001) Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12: 1667-1670
76. Billingham IJ, Cullen MH (2001) The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 12: 1671-1675
77. Baselga J, Pfister D, Cooper MR et al. (2000) Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin. J Clin Oncol 18: 904-914
78. Kris MG, Herbst R, Rischin D et al. (2000) Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD 1839 (Iressa) a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29 (S1), abstr. 233
79. Miller VA, Johnson D, Heelan RT et al. (2001) A Pilot Trial Demonstrates the Safety of ZDI1839 ("Iressa"), an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Combination with Carboplatin (C) and Paclitaxel (P) in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC). Proce ASCO 20, abstr. 1301
80. Langer CJ, Adak S, Thor A et al. (2001) Phase II Eastern Cooperative Oncology Group (ECOG) Pilot Study of Paclitaxel (P), Carboplatin (C), and Trastuzumab (T) in HER-2/neu (+) Advanced Non-Small Cell Lung Cancer (NSCLC): Early Analysis of E2598. Proc ASCO 20, abstr. 1257
81. Smylie M, Mercier R, Aboulafia D et al. (2001) Phase III Study of the Matrix Metalloprotease (MMP) Inhibitor Prinomastat in Patients Having Advanced Non-Small Cell Lung Cancer (NSCLC). Proc ASCO 20, abstr. 1226
82. Johnson DH, DeVore R, Kabbinavar F et al. (2001) Carboplatin (C) + Paclitaxel (T) + RhuMab-VEGF (AVF) May Prolong Survival in Advanced Non-Squamous Lung Cancer. Proc ASCO 20, abstr. 256
83. Schuler M, Hermann R, De Greve JLP et al. (2001) Adenovirus-Mediated Wild-Typ p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study. J Clin Oncol 19: 1750-1758.